Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation

MeSH terms

• Administration, Oral
• Anticoagulants / adverse effects
• Atrial Fibrillation* / complications
• Atrial Fibrillation* / diagnosis
• Atrial Fibrillation* / drug therapy
• Humans
• Stroke* / diagnosis
• Stroke* / etiology
• Stroke* / prevention & control
• Vitamin K